Journal
CURRENT BIOLOGY
Volume 26, Issue 21, Pages R1161-R1166Publisher
CELL PRESS
DOI: 10.1016/j.cub.2016.09.043
Keywords
-
Categories
Funding
- MRC [G0901609] Funding Source: UKRI
- Cancer Research UK [12007, 18673] Funding Source: researchfish
- Medical Research Council [1365527, G0901609] Funding Source: researchfish
- Worldwide Cancer Research [12-1068] Funding Source: researchfish
- Cancer Research UK [12007] Funding Source: Medline
- Medical Research Council [G0901609] Funding Source: Medline
- Worldwide Cancer Research [12-1068] Funding Source: Medline
Ask authors/readers for more resources
Several studies have explored the potential of targeting tumor angiogenesis in cancer treatment. Anti-angiogenesis monotherapy, which reduces blood vessel numbers, may still hold some promise in cancer treatment, but thus far it has only provided a modest effect on overall survival benefits. When combined with standard chemotherapies, some significant improvements in cancer therapy have been reported. However, anti-angiogenesis therapies can have undesirable effects, including the induction of tumor hypoxia and reduction of delivery of chemotherapeutic drugs. Interestingly, anti-angiogenic drugs, such as bevacizumab, when used at lower doses, can actually induce vascular normalization (that is, they improve blood vessel function and flow) and potentially enhance co-administrated chemotherapeutic drug delivery. Unfortunately, vascular normalization is a difficult approach to apply in clinical settings. Thus, there is an urgent need to explore new approaches for modulating the tumor vasculature. Here, we explore how vascular promotion strategies (which enhance blood vessel numbers and leakiness) may be optimized for combination therapies as an alternative option for cancer treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available